Picture EBD Group BioPharm America 2019 Boston September 650x65px
Document › Details

Definiens AG. (2/29/16). "Press Release: Definiens Appoints Michael Rasche Global Head of Sales, Expands Executive Team". Munich.

Region Region ALL
Organisations Organisation Definiens AG
  Group AstraZeneca (Group)
  Organisation 2 Ayoxxa Biosystems GmbH
  Group Ayoxxa (Group)
Products Product Tissue Phenomics™
  Product 2 Definiens Cognition Network Technology®
Persons Person Rasche, Michael (AstraZeneca 201707– promoted CCO at Definiens joined 201602 as SVP Global Sales before Ayoxxa + Dako)
  Person 2 Heydler, Thomas P. (Definiens 200411– CEO)

Diagnostics Industry Veteran Will Lead Customer Acquisition for Rapidly Growing Clinical Business

Definiens, The Tissue Phenomics® Company, today announced that it has appointed Michael Rasche as the company’s Senior Vice President of Global Sales. Rasche will oversee Definiens’ Global Sales Team, with a special focus on accelerating customer acquisition for clinical business at a time of rapid momentum.

“I’m delighted to welcome Michael to the Definiens Team,” said Thomas Heydler, Definiens’ CEO. “Our Tissue Phenomics approach is of high value to both academic researchers and Biopharma in finding new markers that drive therapeutic treatments. Adding Michael’s experience in clinical and personalized medicine will build off our research foundation, helping Definiens and its partners to transform healthcare.”

“I am very excited to be part of the Definiens success story and am passionate to drive the increased usage of our powerful technology for patient stratification and clinical trial enrollment,” commented Rasche. “Tissue Phenomics and Definiens’ Big Data approaches will fast-track the development of tissue diagnostic assays and significantly improve patient outcomes.”

Rasche’s skillset will contribute to further positioning Definiens as a clinical development and diagnostics partner that combines powerful image analysis with data integration and mining. Definiens has been a leader in image analysis for the past decade, but with recent advancements in their proprietary Cognition Network Technology®, Definiens has expanded its ability to datafy tissue features and can now rapidly mine data across genomics, Tissue Phenomics, and clinical outcomes to develop meaningful signatures for patient stratification. Definiens has experienced significant growth in oncology and immune-oncology partnerships with big pharma to develop new stratifying assays, and one of Rasche’s primary initiatives will be to drive continued momentum and support the strategic expansion from research into clinical development and diagnostics.

Rasche is an industry veteran with 25 years of experience in healthcare / life science arena, with particular focus on diagnostics. He joins Definiens from AYOXXA Biosystems where he was Corporate Vice President of Global Commercial Operations. Prior to that he was Corporate Vice President of Global marketing and Business Development for Dako. He has also held leadership positions in with Roche and Bayer Diagnostics both in Europe and Latin America across 9 different countries.

About Definiens

Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker and companion diagnostics development. Definiens’ technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit:

Media Contacts:

Jonathan Moll,
+1 212-398-9680

Record changed: 2016-06-11


Picture [LSUS] – The Business Web Portal 650x112px

More documents for AstraZeneca (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2019 Boston September 650x65px

» top